Abbott Stays Ahead Of Edwards In Transcatheter Mitral Valve Race With Tendyne CE Mark

Tendyne is indicated for the treatment of significant mitral regurgitation in patients who are not candidates for surgery. It complements Abbott’s MitraClip mitral valve repair device and is an important part of the company’s strategy to be the leading structural heart device company.

Tendyne
Abbott's Tendyne transcatheter mitral valve system • Source: Abbott Laboratories

Abbott Laboratories Inc. will market the Tendyne transcatheter mitral valve replacement device alongside its MitraClip transcatheter mitral valve repair system to establish a clear lead in the transcatheter mitral valve market.

Tendyne earned a CE mark for treating significant mitral regurgitation in patients requiring a heart valve replacement who are not...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Approvals

More from Policy & Regulation